Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

Despite significant advances in the field of cancer immunotherapy, the majority of patients
still do not benefit from treatment and must rely on traditional therapies. Dendritic cells have …

Human epidermal growth factor receptor 2–positive (HER2+) breast cancer accounts for~
25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to …

Breast cancer (BC) is the most common cancer in women worldwide. Although substantial
progress has been made in the diagnosis and treatment of breast cancer, the efficacy and …

Dendritic cells (DCs) can present tumoral antigens to T-cells and stimulate T-cell-mediated
anti-tumoral immune responses. In addition to uptaking, processing, and presenting tumoral …

Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive immunity.
DCs have been historically considered as the most effective and potent cell population to …

Dendritic cells (DCs) are a heterogenous population of professional antigen presenting cells
whose main role is diminished in a variety of malignancies, including cancer, leading to …

Purpose AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+
response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides …

Abstract Programmed cell death-1 (PD-1; CD279) is a cell surface receptor that is expressed
in both innate and adaptive immune cells. The role of PD-1 in adaptive immune cells …

Breast cancer (BC) is one of the main causes of cancer-related death worldwide. The
heterogenicity of breast tumors and the presence of tumor resistance, metastasis, and …